CTLA4 and neoplasm: Following the strategy established through IS-panel-10, the combination of STING-LNP and the CTLA4 antibody in the 4T1 tumor model resulted in significant tumor suppression, despite the cancer being resistant to immunotherapy, including immune checkpoint inhibitors.